


Amended Claims

1. **(currently amended)** A compound or a salt thereof, wherein:
 the compound corresponds in structure to the Formula X:



~~Z is selected from the group consisting of C(O), N(R⁶), O, S, S(O), S(O)₂, and N(S(O)₂R⁷);~~

~~R⁶ is selected from the group consisting of hydrogen, formyl, sulfonic-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, carboxy-C₁-C₆-alkyl, C₁-C₆-alkylearbonyl-C₁-C₆-alkyl, R⁸R⁹-aminocarbonyl-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkylearbonyl, carboxy-C₁-C₆-alkylearbonyl, C₁-C₆-alkylearbonyl-C₁-C₆-alkylearbonyl, C₁-C₆-alkoxycarbonyl, carboxy, C₁-C₆-alkylearbonyl, R⁸R⁹-aminocarbonyl, aryl-C₁-C₆-alkyl, aryldarbonyl, bis(C₁-C₆-alkoxy-C₁-C₆-alkyl)-C₁-C₆-alkyl, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, trifluoromethyl-C₁-C₆-alkyl, perfluoro-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, heteroaryldarbonyl, heterocyclyldarbonyl, aryl, heterocyclyl, heteroaryl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, arylsulfonyl, C₁-~~

C_6 -alkylsulfonyl, C_5 - C_6 -heteroarylsulfonyl, carboxy- C_1 - C_6 -alkyl, aminocarbonyl, C_1 - C_6 -alkylimino(R^{10})carbonyl, arylimino(R^{10})carbonyl, C_5 - C_6 -heterocyclylimino(R^{10})carbonyl, arylthio- C_1 - C_6 -alkyl, C_1 - C_6 -alkylthio- C_1 - C_6 -alkyl, arylthio- C_3 - C_6 -alkenyl, C_1 - C_4 -alkylthio- C_3 - C_6 -alkenyl, C_5 - C_6 -heteroaryl- C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkylearbonyl, hydroxy- C_1 - C_6 -alkylearbonyl, thiol- C_1 - C_6 -alkylearbonyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl, aryloxyarbonyl, R^8R^9 -aminoimino(R^{10})methyl, R^8R^9 -amino- C_1 - C_5 -alkylearbonyl, hydroxy- C_1 - C_5 -alkyl, R^8R^9 -aminocarbonyl, R^8R^9 -aminocarbonyl- C_1 - C_6 -alkylearbonyl, hydroxyaminocarbonyl, R^8R^9 -aminosulfonyl, R^8R^9 -aminosulfonyl- C_1 - C_6 -alkyl, R^8R^9 -amino- C_1 - C_6 -alkylsulfonyl, and R^8R^9 -amino- C_1 - C_6 -alkyl;

R^7 is selected from the group consisting of aryl- C_1 - C_6 -alkyl, aryl, heteroaryl, heterocyclyl, C_1 - C_6 -alkyl, C_3 - C_6 -alkynyl, C_3 - C_6 -alkenyl, carboxy- C_1 - C_6 -alkyl, and hydroxy- C_1 - C_6 -alkyl;

as to R^8 and R^9 :

R^8 and R^9 are independently selected from the group consisting of hydrogen, hydroxy, C_1 - C_6 -alkyl, C_1 - C_6 -alkylearbonyl, arylearbonyl, aryl, aryl- C_1 - C_6 -alkyl, heteroaryl, heteroaryl- C_1 - C_6 -alkyl, C_2 - C_6 -alkynyl, C_2 - C_6 -alkenyl, thiol- C_1 - C_6 -alkyl, C_1 - C_6 -alkylthio- C_1 - C_6 -alkyl, cycloalkyl, cycloalkyl- C_1 - C_6 -alkyl, heterocyclyl- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, aryl- C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, hydroxy- C_1 - C_6 -alkyl, carboxy- C_1 - C_6 -alkyl, carboxyaryl- C_1 - C_6 -alkyl, aminocarbonyl- C_1 - C_6 -alkyl, aryloxy- C_1 - C_6 -alkyl, heteroaryloxy- C_1 - C_6 -alkyl, arylthio- C_1 - C_6 -alkyl, heteroarylthio- C_1 - C_6 -alkyl, a sulfoxide of any said thio substituents, a sulfone of any said thio substituents, trifluoromethyl- C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkyl, alkoxycarbonylamino- C_1 - C_6 -alkyl, and amino- C_1 - C_6 -alkyl, wherein:

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl, aryl-C₁-C₆-alkyl, cycloalkyl, and C₁-C₆-alkylearbonyl, or~~

~~R⁸ and R⁹, together with the atom to which they are bonded, form a 5- to 8-membered heterocyclic or heteroaryl ring containing up to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; only one of R⁸ and R⁹ is hydroxy;~~

~~R¹⁰ is selected from the group consisting of hydrogen, hydroxy, C₁-C₆-alkyl, aryl, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl, thiol, C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl, cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aryl-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, carboxy-C₁-C₆-alkyl, carboxyaryl-C₁-C₆-alkyl, aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, arylthio-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, a sulfoxide of any said thio substituents, a sulfone of any said thio substituents, trifluoromethyl-C₁-C₆-alkyl, halo-C₁-C₆-alkyl, alkoxycarbonylamino-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl, aryl-C₁-C₆-alkyl, cycloalkyl, and C₁-C₆-alkylearbonyl;~~

~~E is selected from the group consisting of a bond, -C(O)-, and -S-;~~

~~Y is selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, hydroxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl, alkenyl, heterocyclyl, cycloalkyl, trifluoromethyl, alkoxycarbonyl, and aminoalkyl, wherein:~~

the aryl, heteroaryl, arylalkyl, or heterocyclyl optionally is substituted with up to 2 substituents independently selected from the group consisting of alkylcarbonyl, halo, nitro, arylalkyl, aryl, alkoxy, trifluoroalkyl, trifluoroalkoxy, and amino, wherein:

the amino nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of alkyl and arylalkyl; and

R is selected from the group consisting of hydrogen, cyano, perfluoroalkyl, trifluoromethoxy, trifluoromethylthio, haloalkyl, trifluoromethylalkyl, arylalkoxycarbonyl, aryloxy, carbonyl, hydroxy, halo, alkyl, alkoxy, nitro, thiol, hydroxycarbonyl, aryloxy, arylthio, arylalkyl, aryl, arylcarbonylamino, heteroaryloxy, heteroarylthio, heteroarylalkyl, cycloalkyl, heterocyclyloxy, heterocyclylthio, heterocyclylamino, cycloalkyloxy, cycloalkylthio, heteroarylalkoxy, heteroarylalkylthio, arylalkoxy, arylalkylthio, arylalkylamino, heterocyclyl, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxy, carbonylalkoxy, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkylcarbonyloxy, arylalkylcarbonyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxy, carbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, alkoxy, carbonylalkoxy, alkoxy, carbonylalkylthio, amino, aminocarbonyl, and aminoalkyl, wherein:

the amino nitrogen optionally is substituted with:

up two substituents that are independently selected from the group consisting of alkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, arylalkoxycarbonyl, alkoxy, carbonyl, arylcarbonyl, arylalkylcarbonyl, heteroarylcarbonyl, heteroarylalkylcarbonyl, and alkylcarbonyl, or

two substituents such that the two substituents, together with the amino nitrogen, form a 5- to 8-member heterocyclyl or heteroaryl ring that:

contains from zero to two additional heteroatoms that are independently selected from the group consisting of nitrogen, oxygen, and sulfur,

optionally is substituted with up to two substituents independently selected from the group consisting of aryl, alkyl,

heteroaryl, arylalkyl, heteroarylalkyl, hydroxy, alkoxy, alkylcarbonyl, cycloalkyl, heterocyclalkyl, alkoxycarbonyl, hydroxyalkyl, trifluoromethyl, benzofused heterocyclalkyl, hydroxyalkoxyalkyl, arylalkoxycarbonyl, hydroxycarbonyl, aryloxyalkyl, benzofused heterocyclalkoxy, benzofused cycloalkylcarbonyl, heterocyclalkylcarbonyl, and cycloalkylcarbonyl,

the aminocarbonyl nitrogen is:

unsubstituted,

the reacted amine of an amino acid,

substituted with one or two substituents independently selected from the group consisting of alkyl, hydroxyalkyl, hydroxyheteroarylalkyl, cycloalkyl, arylalkyl, trifluoromethylalkyl, heterocyclalkyl, benzofused heterocyclalkyl, benzofused cycloalkyl, and N,N-dialkylsubstituted alkylamino-alkyl, or

substituted with two substituents such that the two substituents, together with the aminocarbonyl nitrogen, form a 5- to 8-member heterocycl or heteroaryl ring that optionally is substituted with up to two substituents independently selected from the group consisting of alkyl, alkoxycarbonyl, nitro, heterocyclalkyl, hydroxy, hydroxycarbonyl, aryl, arylalkyl, heteroaralkyl, and amino, wherein the amino nitrogen optionally is substituted with:

two substituents independently selected from the group consisting of alkyl, aryl, and heteroaryl; or

two substituents such that the two substituents, together with the amino nitrogen, form a 5- to 8-member heterocycl or heteroaryl ring, and


the aminoalkyl nitrogen optionally is substituted with:

up to two substituents independently selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, arylalkoxycarbonyl, alkoxycarbonyl, and alkylcarbonyl, or

two substituents such that the two substituents, together with the aminoalkyl nitrogen, form a 5- to 8-member heterocyclyl or heteroaryl ring.

2. **(original)** A compound or salt according to claim 1, wherein R is halo.

3. **(currently amended)** A compound or salt according to claim 1, wherein the compound corresponds in structure to Formula XA:



4. **(original)** A compound or salt according to claim 3, wherein the salt is a pharmaceutically acceptable salt.

5. **(original)** A compound or salt according to claim 3, wherein Y is selected from the group consisting of aryl, arylalkyl, cycloalkyl, heteroaryl, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkyl, heterocyclyl, and cycloalkyl, wherein:

the aryl, heteroaryl, arylalkyl, or heterocyclyl optionally is substituted with up to 2 substituents independently selected from the group consisting of alkylcarbonyl, halo, nitro, arylalkyl, aryl, alkoxy, trifluoroalkyl, trifluoroalkoxy, and amino, wherein:

the amino nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of alkyl and arylalkyl.


6. **(original)** A compound or salt according to claim 3, wherein E is a bond.

7. **(original)** A compound or salt according to claim 3, wherein E is -C(O)-.

8. **(original)** A compound or salt according to claim 3, wherein E is -S-.

Claims 9-13 (canceled)

14. **(currently amended)** A compound or a salt thereof, wherein:
 the compound corresponds in structure to Formula X:



E is selected from the group consisting of a bond, -C(O)-, and -S-;

~~Z is selected from the group consisting of -C(O)-, N(R⁶), O-, S-, and -S(O)₂-;~~

~~R⁶ is selected from the group consisting of hydrogen, arylalkoxycarbonyl, alkylcarbonyl, alkyl, alkoxyalkyl, cycloalkyl, heteroarylcabonyl, heteroaryl,~~

~~cycloalkylalkyl, alkylsulfonyl, haloalkylcarbonyl, alkenyl, alkynyl, and R⁸R⁹-
aminoalkylcarbonyl;~~

~~as to R⁸ and R⁹:~~

~~R⁸ and R⁹ are independently selected from the group consisting of hydrogen,
alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxyalkyl, heteroarylalkyl,
cycloalkylalkyl, heterocyclylcarbonyl, haloalkyl, and aminoalkyl, wherein:~~

~~the aminoalkyl nitrogen optionally is substituted with up to two
substituents independently selected from the group consisting of alkyl, or~~

~~R⁸ and R⁹, together with the atom to which they are bonded, form a 5- to 8-
membered heterocyclyl or heteroaryl containing up to 3 heteroatoms independently
selected from the group consisting of nitrogen, oxygen, and sulfur, wherein:~~

~~any such heterocyclyl optionally is substituted with one or more
substituents independently selected from the group consisting of hydroxy,
keto, carboxy, alkoxyalkyl, hydroxyalkyl, hydroxyalkoxyalkyl,
alkoxycarbonylalkyl, heterocyclylalkyl, alkoxycarbonyl, and aminoalkyl,
wherein:~~

~~the aminoalkyl nitrogen optionally is substituted with up to
two substituents independently selected from the group consisting of
alkyl; and~~

Y is selected from the group consisting of cycloalkyl, 2,3-dihydroindolyl, heterocyclyl,
aryl, heteroaryl, arylalkyl, and heteroarylalkyl, wherein:

any such substituent optionally is substituted with one or more optionally
substituted substituents independently selected from the group consisting of halogen,
hydroxy, keto, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkoxy, alkylcarbonyl, haloalkoxy,
alkylthio, alkoxyalkyl, alkoxycarbonylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkyloxy,
cycloalkylalkoxy, cycloalkylalkoxyalkyl, aryl, arylalkyl, arylalkoxy, heterocyclyl,
heterocyclylalkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonylalkyl,
alkylsulfonyl, amino, aminoalkyl, and aminocarbonyl, wherein:


any such substituent optionally is substituted with one or more substituents
independently selected from the group consisting of halogen, nitro, alkyl,

haloalkyl, alkoxy, haloalkoxy, and alkylcarbonyl, and

the nitrogen of the amino, aminoalkyl, or aminocarbonyl optionally is substituted with up to two substituents independently selected from the group consisting of alkyl and cycloalkylalkyl; and

R is selected from the group consisting of hydrogen and halogen.

15. **(currently amended)** A compound or salt according to claim 14, wherein the compound corresponds in structure to Formula XA:



Claims 16-25 (canceled).

26. **(original)** A compound or salt according to claim 15, wherein E is -C(O)-.

Claims 27 and 28 (canceled).

29. **(currently amended)** A compound or salt according to claim 26, wherein:

~~R⁶ is selected from the group consisting of hydrogen, aryl-C₁-C₆-alkoxycarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl,~~

~~heteroaryl, heteroarylecarbonyl, halo-C₁-C₆-alkylecarbonyl, and R⁸R⁹-amino-C₁-C₆-alkylecarbonyl;~~

~~as to R⁸ and R⁹:~~

~~R⁸ and R⁹ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, heterocycylecarbonyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl, or~~

~~R⁸ and R⁹, together with the atom to which they are bonded, form a heterocyclyl or heteroaryl containing up to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein:~~

~~any such heterocyclyl optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, keto, carboxy, hydroxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl; and~~

Y is selected from the group consisting of heterocyclyl, aryl, heteroaryl, and arylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-

C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-C₁-C₆-alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl, and

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

30. **(original)** A compound or salt according to claim 29, wherein Y is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-C₁-C₆-alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl, and

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

31. **(original)** A compound or salt according to claim 29, wherein Y is thienyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-

C₁-C₆-alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl, and

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

Claims 32 and 33 (canceled).

34. **(currently amended)** A compound or salt according to claim 26, wherein:

~~R⁶ is selected from the group consisting of C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, and C₁-C₆-alkylsulfonyl; and~~

Y is selected from the group consisting of aryl, heteroaryl, arylmethyl, and heteroarylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl.

35. **(original)** A compound or salt according to claim 34, wherein Y is phenyl or phenylmethyl, wherein:

the phenyl or phenylmethyl optionally is substituted with one or more substituents

independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl.

Claims 36-40 (canceled).

41. **(original)** A compound or salt according to claim 34, wherein Y is thienyl or thienylmethyl, wherein:

the thienyl or thienylmethyl optionally is substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl.

Claims 42-46 (canceled).

47. **(original)** A compound or salt according to claim 15, wherein E is a bond.

Claims 48 and 49 (canceled).

50. (currently amended) A compound or salt according to claim 47, wherein:

~~R⁶ is selected from the group consisting of hydrogen, aryl-C₁-C₆-alkoxycarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, heteroaryl, heteroarylecarbonyl, halo-C₁-C₆-alkylecarbonyl, and R⁸R⁹-amino-C₁-C₆-alkylecarbonyl;~~

~~as to R⁸ and R⁹:~~

~~R⁸ and R⁹ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, heteroecylecarbonyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl, or~~

~~R⁸ and R⁹, together with the atom to which they are bonded, form a heteroecyl or heteroaryl containing up to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein:~~

~~any such heteroecyl optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, keto, carboxy, hydroxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, heteroecyl-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl;~~

Y is selected from the group consisting of aryl, 2,3-dihydroindolyl, heterocyclyl, and heteroaryl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, keto, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkyl, halo-C₁-C₆-alkoxy, aryl, aminocarbonyl, and C₁-C₆-alkylsulfonyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, halo-C₁-C₆-alkyl, and halo-C₁-C₆-alkoxy, and

the nitrogen of the aminocarbonyl optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl.

51. **(original)** A compound or salt according to claim 50, wherein Y is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, keto, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkyl, halo-C₁-C₆-alkoxy, aryl, aminocarbonyl, and C₁-C₆-alkylsulfonyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, halo-C₁-C₆-alkyl, and halo-C₁-C₆-alkoxy, and

the nitrogen of the aminocarbonyl optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl.

52. **(currently amended)** A compound or salt according to claim 47, wherein:

~~R⁶ is selected from the group consisting of C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, and C₁-C₆-alkylsulfonyl; and~~

Y is selected from the group consisting of heteroaryl, aryl, and heterocyclyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-

alkoxy, and aryl, wherein:

the aryl optionally is substituted with one or more substituents
independently selected from the group consisting of halo-C₁-C₆-alkyl.

53. (original) A compound or salt according to claim 50, wherein Y is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, and aryl, wherein:

the aryl optionally is substituted with one or more substituents independently selected from the group consisting of halo-C₁-C₆-alkyl.

54. (original) A compound or salt according to claim 15, wherein E is -S-.

Claims 55 and 56 (canceled).

57. (currently amended) A compound or salt according to claim 54, wherein:

~~R⁶ is selected from the group consisting of hydrogen, aryl-C₁-C₆-alkoxycarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, heteroaryl, heteroarylecarbonyl, halo-C₁-C₆-alkylecarbonyl, and R⁸R⁹-amino-C₁-C₆-alkylecarbonyl;~~

~~as to R⁸ and R⁹:~~

~~R⁸ and R⁹ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, heterocyclylecarbonyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl, or~~

~~R⁸ and R⁹, together with the atom to which they are bonded, form a heterocyclyl or heteroaryl containing up to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein:~~

~~any such heterocyclyl optionally is substituted with one or more substituents independently selected from the group consisting of hydroxy, keto, carboxy, hydroxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, and amino-C₁-C₆-alkyl, wherein:~~

~~the amino-C₁-C₆-alkyl nitrogen optionally is substituted with up to 2 substituents independently selected from the group consisting of C₁-C₆-alkyl;~~

Y is selected from the group consisting of cycloalkyl, aryl, arylmethyl, and heteroaryl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, halo-C₁-C₆-alkyl, and halo-C₁-C₆-alkoxy.

58. (currently amended) A compound or salt according to claim 54, wherein:

~~R⁶ is selected from the group consisting of C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, and C₁-C₆-alkylsulfonyl; and~~

Y is heteroaryl.


59. **(currently amended)** A method for ~~preventing or~~ treating a pathological condition ~~associated with matrix metalloprotease activity in an a-host~~ animal, wherein:

the method comprises administering a compound recited in claim 1 (or a pharmaceutically acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to ~~prevent or~~ treat the condition;

the condition is treatable by inhibiting matrix metalloprotease activity; and

the condition is selected from the group consisting of tissue destruction, a fibrotic disease, matrix weakening, defective injury repair, a cardiovascular disease, a pulmonary disease, a kidney disease, and a central nervous system disease.

60. **(currently amended)** A method according to claim 59, wherein the compound corresponds in structure to ~~a compound recited in claim 3~~ Formula XA:



61. **(original)** A method according to claim 59, wherein the condition is selected from the group consisting of osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion, tumor metastasis, tumor angiogenesis, a decubitis ulcer, a gastric ulcer, a corneal ulcer, periodontal disease, liver cirrhosis, fibrotic lung disease, otosclerosis, atherosclerosis, multiple sclerosis, dilated cardiomyopathy, epidermolysis bullosa, aortic aneurysm, weak injury repair, an adhesion, scarring, congestive heart failure, coronary thrombosis, emphysema, proteinuria, and Alzheimer's disease.

62. **(original)** A method according to claim 59, wherein the condition is selected from the group consisting of rheumatoid arthritis, osteoarthritis, septic arthritis, corneal ulceration, epidermal ulceration, gastric ulceration, tumor metastasis, tumor invasion, tumor angiogenesis,


periodontal disease, proteinuria, Alzheimer's disease, coronary thrombosis, bone disease, and defective injury repair.

Claim 63 (canceled).

64. **(currently amended)** A method for ~~preventing or~~ treating a **pathological** condition ~~associated with matrix metalloprotease activity in an a host~~ animal, **wherein:**
the condition is treatable by inhibiting matrix metalloprotease-2, matrix metalloprotease-9, and/or matrix metalloprotease-13 activity; and

the method comprising administering a compound recited in claim 1 (or a pharmaceutically-acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to inhibit matrix metalloprotease-2, matrix metalloprotease-9, and/or matrix metalloprotease-13.

65. **(currently amended)** A method according to claim 64, wherein the compound corresponds in structure to ~~a compound recited in claim 3~~ **Formula XA:**



66. **(currently amended)** A method according to claim 64, wherein **the compound** **inhibits** matrix metalloprotease-13 ~~is inhibited~~ selectively over both matrix metalloprotease-1 and matrix metalloprotease-14.

Claims 67 and 68 (canceled).

69. **(currently amended)** A method for ~~preventing or~~ treating a pathological condition ~~associated with matrix metalloprotease activity in an a-host~~ animal, wherein:

the method comprises administering a compound recited in claim 1 (or a pharmaceutically-acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to ~~prevent or~~ treat the condition, and

the condition is treatable by inhibiting ~~associated with~~ TNF- α convertase activity.


Claims 70 and 71 (canceled).

72. **(currently amended)** A method for ~~preventing or~~ treating a pathological condition ~~associated with aggrecanase activity in an a-host~~ animal, wherein:

the condition is treatable by inhibiting aggrecanase activity; and

the method comprises administering a compound of claim 1 (or a pharmaceutically-acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to ~~prevent or~~ treat the condition.

73. **(currently amended)** A method according to claim 72, wherein the compound corresponds in structure to ~~a compound recited in claim 3~~ Formula XA:



Claims 74-78 (canceled).


79. **(currently amended)** A method for ~~preventing or~~ treating a **pathological** condition ~~associated with matrix metalloprotease activity in an a host~~ animal, wherein:

the method comprises administering a compound recited in claim 14 (or a pharmaceutically acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to ~~prevent or~~ treat the condition;

the condition is treatable by inhibiting matrix metalloprotease activity; and

the condition is selected from the group consisting of tissue destruction, a fibrotic disease, matrix weakening, defective injury repair, a cardiovascular disease, a pulmonary disease, a kidney disease, and a central nervous system disease.

80. **(currently amended)** A method according to claim 79, wherein the compound corresponds in structure to ~~a compound recited in claim 15~~ **Formula XA:**



81. **(currently amended)** A method according to claim 79, wherein ~~the compound corresponds in structure to a compound recited in claim 29~~ **Y is selected from the group consisting of heterocyclyl, aryl, heteroaryl, and arylmethyl, wherein:**

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-C₁-C₆-alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen,

nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl,
and

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is
substituted with up to two substituents independently selected from the
group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

82. (currently amended) A method according to claim 79, wherein ~~the compound corresponds in structure to a compound recited in claim 34~~ Y is selected from the group consisting of aryl, heteroaryl, arylmethyl, and heteroarylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents
independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-
C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-
cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-
cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-
C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is
substituted with up to two substituents independently selected from the
group consisting of C₁-C₆-alkyl.


83. (original) A method according to claim 79, wherein the condition is selected from the group consisting of osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion, tumor metastasis, tumor angiogenesis, a decubitus ulcer, a gastric ulcer, a corneal ulcer, periodontal disease, liver cirrhosis, fibrotic lung disease, otosclerosis, atherosclerosis, multiple sclerosis, dilated cardiomyopathy, epidermolysis bullosa, aortic aneurysm, weak injury repair, an adhesion, scarring, congestive heart failure, coronary thrombosis, emphysema, proteinuria, and Alzheimer's disease.

84. (currently amended) A method for ~~preventing or~~ treating a pathological condition ~~associated with matrix metalloprotease activity in an a host~~ animal, wherein:

the condition is treatable by inhibiting matrix metalloprotease-2, matrix metalloprotease-9, and/or matrix metalloprotease-13 activity; and

the method comprising administering a compound recited in claim 14 (or a pharmaceutically-acceptable salt thereof) to the **[[host]]** animal in an amount effective to inhibit matrix metalloprotease-2, matrix metalloprotease-9, and/or matrix metalloprotease-13.

85. **(currently amended)** A method according to claim 84, herein the compound corresponds in structure to ~~a compound recited in claim 15~~ Formula XA:



86. **(currently amended)** A method according to claim 84, wherein ~~the compound corresponds in structure to a compound recited in claim 29~~ Y is selected from the group consisting of heterocyclyl, aryl, heteroaryl, and arylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-C₁-C₆-alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl, and

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

87. (currently amended) A method according to claim 84, wherein ~~the compound corresponds in structure to a compound recited in claim 34~~ Y is selected from the group consisting of aryl, heteroaryl, arylmethyl, and heteroarylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl.

88. (currently amended) A method according to claim 84, wherein the compound inhibits matrix metalloprotease-13 ~~is inhibited~~ selectively over both matrix metalloprotease-1 and matrix metalloprotease-14.

Claims 89 and 90 (canceled).

91. (currently amended) A method for ~~preventing or~~ treating a pathological condition ~~associated with matrix metalloprotease activity in an a host~~ animal, wherein:

the method comprises administering a compound recited in claim 14 (or a pharmaceutically-acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to ~~prevent or~~ treat the condition, and

the condition is treatable by inhibiting ~~associated with~~ TNF- α convertase activity.


Claim 92-95 (canceled).

96. **(currently amended)** A method for ~~preventing or~~ treating a pathological condition ~~associated with aggrecanase activity~~ in ~~an a host~~ animal, wherein:

the condition is treatable by inhibiting aggrecanase activity; and

the method comprises administering a compound of claim 14 (or a pharmaceutically-acceptable salt thereof) to the ~~[[host]]~~ animal in an amount effective to ~~prevent or~~ treat the condition.

97. **(currently amended)** A method according to claim 96, herein the compound corresponds in structure to ~~a compound recited in claim 15~~ Formula XA:



98. **(currently amended)** A method according to claim 96, wherein ~~the compound corresponds in structure to a compound recited in claim 29~~ Y is selected from the group consisting of heterocyclyl, aryl, heteroaryl, and arylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-C₁-C₆-alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl,

and

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

99. (currently amended) A method according to claim 96, wherein ~~the compound corresponds in structure to a compound recited in claim 34~~ **Y is selected from the group consisting of aryl, heteroaryl, arylmethyl, and heteroarylmethyl, wherein:**


any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl.

Claims 100-104 (canceled).


105. (original) A pharmaceutical composition comprising a compound recited in claim 1 or a pharmaceutically acceptable salt thereof.

106. **(currently amended)** A pharmaceutical composition according to claim 105, wherein the compound corresponds in structure to ~~a compound recited in claim 3~~ Formula XA:



107. **(original)** A pharmaceutical composition comprising a compound recited in claim 14 or a pharmaceutically acceptable salt thereof.

108. **(currently amended)** A pharmaceutical composition according to claim 107, wherein the compound corresponds in structure to ~~a compound recited in claim 15~~ Formula XA:



109. **(currently amended)** A pharmaceutical composition according to claim 107, wherein ~~the compound corresponds in structure to a compound recited in claim 29~~ Y is selected from the group consisting of heterocyclyl, aryl, heteroaryl, and arylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkylcarbonyl, halo-C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, aryl, aryl-C₁-C₆-alkyl, aryl-C₁-C₆-

alkoxy, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, heteroaryl, heteroarylcarbonyl, heterocyclylcarbonyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, nitro, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, and C₁-C₆-alkylcarbonyl, and


the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl and C₃-C₆-cycloalkyl-C₁-C₆-alkyl.

110. (currently amended) A pharmaceutical composition according to claim 107, wherein ~~the compound corresponds in structure to a compound recited in claim 34~~ Y is selected from the group consisting of aryl, heteroaryl, arylmethyl, and heteroarylmethyl, wherein:

any such substituent optionally is substituted with one or more substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, amino, and amino-C₁-C₆-alkyl, wherein:

the nitrogen of the amino or amino-C₁-C₆-alkyl optionally is substituted with up to two substituents independently selected from the group consisting of C₁-C₆-alkyl.

111. **(new)** A compound or salt according to claim 14, wherein the compound corresponds in structure to the following formula:



112. **(new)** A method according to claim 59, wherein the condition is osteoarthritis.

113. **(new)** A method according to claim 79, wherein the condition is osteoarthritis.